HIF PH inhibitor - 3SBioAlternative Names: HIF-PH inhibitor; SSS 17
Latest Information Update: 25 Jan 2016
At a glance
- Originator 3SBio
- Class Antianaemics; Small molecules
- Mechanism of Action EGLN2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anaemia
Most Recent Events
- 22 Jan 2016 Preclinical trials in Anaemia in China (PO)
- 22 Jan 2016 3SBio announces intention to submit IND to China FDA in 2016